(NASDAQ: GRAL) Grail's forecast annual revenue growth rate of 12.41% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.13%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.36%.
Grail's revenue in 2025 is $130,711,000.On average, 1 Wall Street analysts forecast GRAL's revenue for 2025 to be $5,416,169,257, with the lowest GRAL revenue forecast at $5,416,169,257, and the highest GRAL revenue forecast at $5,416,169,257. On average, 1 Wall Street analysts forecast GRAL's revenue for 2026 to be $6,056,785,238, with the lowest GRAL revenue forecast at $6,056,785,238, and the highest GRAL revenue forecast at $6,056,785,238.
In 2027, GRAL is forecast to generate $6,353,170,855 in revenue, with the lowest revenue forecast at $6,353,170,855 and the highest revenue forecast at $6,353,170,855.